300558 贝达药业
已收盘 11-10 15:00:00
资讯
新帖
简况
公司问答丨贝达药业：目前在mRNA领域暂无相关布局
格隆汇 · 15:33
公司问答丨贝达药业：目前在mRNA领域暂无相关布局
贝达药业：BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物
证券之星 · 11-06
贝达药业：BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物
贝达药业：截至2026年9月30日，公司股东户数为49,213户
证券之星 · 11-06
贝达药业：截至2026年9月30日，公司股东户数为49,213户
贝达药业：公司将持续完善“研发投入－产品商业化－收益再投入”的良性循环机制
证券之星 · 11-06
贝达药业：公司将持续完善“研发投入－产品商业化－收益再投入”的良性循环机制
贝达药业：QY201用于治疗中重度特应性皮炎适应症的临床研究已处在Ⅲ期临床阶段
证券之星 · 11-06
贝达药业：QY201用于治疗中重度特应性皮炎适应症的临床研究已处在Ⅲ期临床阶段
贝达药业：受合作伙伴临床研究未达终点影响计提减值
证券之星 · 11-06
贝达药业：受合作伙伴临床研究未达终点影响计提减值
贝达药业：Equinox与卡南吉系相互独立的会计主体
证券之星 · 11-06
贝达药业：Equinox与卡南吉系相互独立的会计主体
贝达药业：公司尚未有ADC产品项目立项开发
证券之星 · 11-06
贝达药业：公司尚未有ADC产品项目立项开发
贝达药业：埃克替尼和曲妥珠单抗继续纳入《国家基本药物目录（2026年版）》
证券之星 · 11-06
贝达药业：埃克替尼和曲妥珠单抗继续纳入《国家基本药物目录（2026年版）》
贝达药业：凯铭投资本次办理延期购回的质押股份2,750,000股
证券之星 · 11-06
贝达药业：凯铭投资本次办理延期购回的质押股份2,750,000股
贝达药业（300558）11月4日主力资金净买入3983.64万元
证券之星 · 11-05
贝达药业（300558）11月4日主力资金净买入3983.64万元
贝达药业涨16.01%，东海证券二个月前给出“买入”评级
证券之星 · 11-02
贝达药业涨16.01%，东海证券二个月前给出“买入”评级
贝达药业（300558）2026年三季报简析：增收不增利，应收账款上升
证券之星 · 10-31
贝达药业（300558）2026年三季报简析：增收不增利，应收账款上升
贝达药业：关于股东股份质押变动的公告
同花顺 · 10-30
贝达药业：关于股东股份质押变动的公告
国金证券：给予贝达药业买入评级
证券之星 · 10-29
国金证券：给予贝达药业买入评级
贝达药业：第五届董事会第五次会议决议公告
同花顺 · 10-28
贝达药业：第五届董事会第五次会议决议公告
贝达药业最新公告：拟受让杭州晟斯生物长效生长激素项目技术权益
证券之星 · 10-28
贝达药业最新公告：拟受让杭州晟斯生物长效生长激素项目技术权益
贝达药业最新公告：前三季度净利润同比下降12.20%
证券之星 · 10-28
贝达药业最新公告：前三季度净利润同比下降12.20%
10月27日贝达药业跌5.36%，广发医疗保健股票A基金重仓该股
证券之星 · 10-27
10月27日贝达药业跌5.36%，广发医疗保健股票A基金重仓该股
贝达药业：控股股东凯铭投资股份质押变动
同花顺 · 10-26
贝达药业：控股股东凯铭投资股份质押变动
加载更多
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":46.3,"timestamp":1794294189000,"preClose":46.77,"halted":0,"volume":5492757,"delay":0,"changeRate":-0.01,"floatShares":422000000,"shares":423000000,"eps":0.63,"marketStatus":"已收盘","change":-0.47,"latestTime":"11-10 15:00:00","open":47.1,"high":47.58,"low":46.01,"amount":255000000,"amplitude":0.0336,"askPrice":46.31,"askSize":3,"bidPrice":46.3,"bidSize":23,"shortable":0,"etf":0,"ttmEps":0.63,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794360600000},"marketStatusCode":5,"adr":0,"adjPreClose":46.77,"symbolType":"stock","openAndCloseTimeList":[[1794274200000,1794281400000],[1794286800000,1794294000000]],"highLimit":51.45,"lowLimit":42.09,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423331685,"isCdr":false,"pbRate":3.03,"roa":"--","peRate":73.492063,"roe":"4.26%","epsLYR":0.73,"committee":0.326667,"marketValue":19600000000,"turnoverRate":0.013,"status":1,"floatMarketCap":19547000000},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2682361543","title":"公司问答丨贝达药业：目前在mRNA领域暂无相关布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2682361543","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682361543?lang=zh_cn&edition=full","pubTime":"2026-11-10 15:33","pubTimestamp":1794295982,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681485497","title":"贝达药业：BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=2681485497","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681485497?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:51","pubTimestamp":1793958671,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。请问董秘，贵公司的BPI-572270临床前数据优异，具备BIC潜质，覆盖靶点广泛，安全性和初步疗效突出，是否有与礼来默沙东等有对外合作授权？感谢您对BPI-572270的关注。BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物。公司高度重视该项目的对外合作，将持续与意向合作方进行充分沟通，如有重大合作进展，公司将及时公告披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600029344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681851724","title":"贝达药业：截至2026年9月30日，公司股东户数为49,213户","url":"https://stock-news.laohu8.com/highlight/detail?id=2681851724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681851724?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:42","pubTimestamp":1793958153,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)11月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年10月10日公司的股东人数是多少？谢谢贝达药业回复：您好！截至2026年9月30日，公司股东户数为49,213户。公司会定期更新股东人数信息，您可以通过公司官网（https://www.bettapharma.com/）——投资者关系——互动交流栏目查询最新的股东人数数据。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600029142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681512088","title":"贝达药业：公司将持续完善“研发投入－产品商业化－收益再投入”的良性循环机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2681512088","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681512088?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:42","pubTimestamp":1793958152,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。公司研发投入的会计处理严格遵循企业会计准则的相关规定。2026年1-9月，公司研发投入35,673.21万元，已按照企业会计准则的规定进行费用化或资本化会计处理。公司将持续完善“研发投入－产品商业化－收益再投入”的良性循环机制，集中资源，聚焦核心项目开发，提升研发投入产出的效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600029140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681851202","title":"贝达药业：QY201用于治疗中重度特应性皮炎适应症的临床研究已处在Ⅲ期临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2681851202","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681851202?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:39","pubTimestamp":1793957961,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。投资者提问：近日，杭州启元生物的QY201成人中重度特异性皮炎适应症拟纳入突破性治疗认定进行公示，表明该药物技术水平和疗效优质高效。公司通过杭州贝橙创业投资合伙企业布局了启元生物，其核心药物QY201用于治疗中重度特应性皮炎适应症的临床研究已处在Ⅲ期临床阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600029108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681514988","title":"贝达药业：受合作伙伴临床研究未达终点影响计提减值","url":"https://stock-news.laohu8.com/highlight/detail?id=2681514988","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681514988?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:38","pubTimestamp":1793957886,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。公司已于2026年10月28日披露《2026年第三季度报告》。受合作伙伴EyePoint公布DURAVYU治疗wAMD的两项Ⅲ期临床研究未达到预设主要终点影响，公司已对相关资产计提了减值准备。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600029095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681851907","title":"贝达药业：Equinox与卡南吉系相互独立的会计主体","url":"https://stock-news.laohu8.com/highlight/detail?id=2681851907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681851907?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:37","pubTimestamp":1793957842,"startTime":"0","endTime":"0","summary":"Equinox与卡南吉系相互独立的会计主体，Equinox持有伏罗尼布中国以外权益，卡南吉持有伏罗尼布中国权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600029081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681851699","title":"贝达药业：公司尚未有ADC产品项目立项开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2681851699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681851699?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:30","pubTimestamp":1793957458,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。这是这家以肺癌小分子起家的公司，第一次把大分子药物送到 FDA 的审评桌上。分子类型EGFR×c-MET 双抗 ADC。请问董秘，贝达药业有没有同类药物布局？公司尚未有ADC产品项目立项开发。在EGFR/c-MET靶点方向，公司拥有EGFR/c-MET双特异性抗体MCLA-129在中国的独家开发和商业化权益。如有重大进展或合作事项，公司将及时公告披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600028962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681851660","title":"贝达药业：埃克替尼和曲妥珠单抗继续纳入《国家基本药物目录（2026年版）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681851660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681851660?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:30","pubTimestamp":1793957457,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。投资者提问：9款上市药物，收入三季度同比仅增加7.1%，是增长太乏力还是老药下降太快贝达药业回复：您好！2026年7月，埃克替尼和曲妥珠单抗继续纳入《国家基本药物目录》，贝伐珠单抗新增入选该目录；9月，恩沙替尼用于ALK阳性IB期至IIIB期NSCLC术后辅助治疗的新适应症获得NMPA批准上市，同月恩沙替尼欧洲上市许可申请获得EMA人用药品委员会积极意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600028960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681851650","title":"贝达药业：凯铭投资本次办理延期购回的质押股份2,750,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681851650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681851650?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:30","pubTimestamp":1793957457,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)11月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问2026-10-26公告披露的质押变动公告，质押股数450,000股，是否包含在延期购回情况2,750,000股数中？贝达药业回复：您好！根据公司于2026年10月26日披露的《关于股东股份质押变动的公告》（公告编号：2026-067），凯铭投资本次办理延期购回的质押股份2,750,000股，另补充质押450,000股，即总的质押股数增加450,000股。具体情况请查阅相关公告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600028961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681907760","title":"贝达药业（300558）11月4日主力资金净买入3983.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681907760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681907760?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:23","pubTimestamp":1793841790,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月4日收盘，贝达药业报收于48.27元，上涨7.58%，换手率4.57%，成交量19.3万手，成交额9.13亿元。近5日资金流向一览见下表：贝达药业融资融券信息显示，融资方面，当日融资买入5170.81万元，融资偿还4822.74万元，融资净买入348.07万元。贝达药业主营业务：致力于新药研发和推广,以解决肺癌等恶性肿瘤治疗领域中未被满足的临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500010945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680305737","title":"贝达药业涨16.01%，东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680305737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680305737?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:27","pubTimestamp":1793611640,"startTime":"0","endTime":"0","summary":"今日贝达药业涨16.01%，收盘报46.52元。2026年8月12日，东海证券研究员杜永宏发布了对贝达药业的研报《公司简评报告：产品矩阵持续丰富，研发进展快速推进》，该研报对贝达药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为37.98%。贝达药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200025159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679226330","title":"贝达药业（300558）2026年三季报简析：增收不增利，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2679226330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679226330?lang=zh_cn&edition=full","pubTime":"2026-10-31 07:52","pubTimestamp":1793404373,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期贝达药业发布2026年三季报。截至本报告期末，公司营业总收入29.1亿元，同比上升7.1%，归母净利润2.78亿元，同比下降12.2%。本报告期贝达药业应收账款上升，应收账款同比增幅达104.49%。营业成本变动幅度为35.19%,原因:药品销量增加。持有贝达药业最多的基金为广发医疗保健股票A，目前规模为35.75亿元，最新净值1.6862，较上一交易日下跌0.78%，近一年下跌10.57%。本文数据来源于贝达药业2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100017350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679212226","title":"贝达药业：关于股东股份质押变动的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2679212226","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679212226?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:08","pubTimestamp":1793365680,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月30日，贝达药业发布公告称，公司今日接到股东宁波凯铭投资管理合伙企业(有限合伙)函告，获悉凯铭投资持有本公司的部分股份发生质押变动，本 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261030/c681313850.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261030/c681313850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679423107","title":"国金证券：给予贝达药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2679423107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679423107?lang=zh_cn&edition=full","pubTime":"2026-10-29 13:09","pubTimestamp":1793250552,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕近期对贝达药业进行研究并发布了研究报告《恩沙持续拓展，创新管线加速推进》，给予贝达药业买入评级。商业化方面，9月恩沙替尼ALK阳性IB期至IIIB期NSCLC术后辅助治疗适应症获NMPA批准，为其在国内获批的第三项适应症。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级3家，增持评级2家；过去90天内机构目标均价为77.8。本文数据来源于国金证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900028303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678493264","title":"贝达药业：第五届董事会第五次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2678493264","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678493264?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:02","pubTimestamp":1793192520,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月28日，贝达药业发布公告称，公司于2026年10月28日召开第五届董事会第五次会议，审议通过《关于计提资产减值准备的议案》《关于增加2026年日 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261028/c681207208.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261028/c681207208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678462169","title":"贝达药业最新公告：拟受让杭州晟斯生物长效生长激素项目技术权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2678462169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678462169?lang=zh_cn&edition=full","pubTime":"2026-10-28 19:49","pubTimestamp":1793188197,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司拟与杭州晟斯生物签订《技术转让协议》，受让后者拥有的长效生长激素SS202项目技术资料、特定分子及其制备和应用权益。开发里程碑合计款4000万元，产品商业化后按约定比例支付销售提成。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800044245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678462856","title":"贝达药业最新公告：前三季度净利润同比下降12.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678462856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678462856?lang=zh_cn&edition=full","pubTime":"2026-10-28 19:39","pubTimestamp":1793187593,"startTime":"0","endTime":"0","summary":"贝达药业公告称，前三季度实现营业收入29.10亿元，同比增长7.10%；归属于上市公司股东的净利润2.78亿元，同比下降12.20%。本期业绩变动主要受计提商誉减值损失等因素影响，公司2026年1-9月计提资产减值准备1.52亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800043422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678612470","title":"10月27日贝达药业跌5.36%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678612470","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678612470?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:05","pubTimestamp":1793091957,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日贝达药业跌5.36%，收盘报39.9元，换手率1.85%，成交量7.8万手，成交额3.2亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.7548，较上一交易日上涨0.38%，近一年下跌9.28%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700031843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678160063","title":"贝达药业：控股股东凯铭投资股份质押变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2678160063","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678160063?lang=zh_cn&edition=full","pubTime":"2026-10-26 19:46","pubTimestamp":1793015160,"startTime":"0","endTime":"0","summary":"10月26日，贝达药业(300558.SZ)公告称，公司控股股东一致行动人凯铭投资新增补充质押45万股，占其所持股份0.56%、占公司总股本0.11%，质权人为浙商证券，质押用途为补充质押，质押期限为202 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261026/c681100087.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261026/c681100087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794300386891,"stockEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.0343},{"period":"3month","weight":-0.3134},{"period":"6month","weight":-0.0842},{"period":"1year","weight":-0.1349},{"period":"ytd","weight":0.0048}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0401},{"period":"3month","weight":-0.0695},{"period":"6month","weight":-0.1371},{"period":"1year","weight":-0.0842},{"period":"ytd","weight":-0.0776}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"49213人(较上一季度减少3.47%)","perCapita":"8578股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"42333万元","survey":" 贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}